| 16 Sept 2026, 15:05 | Amplia Presents at E&P Healthcare Conference 2026 | Presentations | — | 03026 |
| 15 Sept 2026, 08:21 | Amplia and ANZGOG Finalise Protocol for Ovarian Cancer Trial | Company Update | — | 11001 |
| 9 Sept 2026, 17:24 | Notification regarding unquoted securities - ATX | Securities Administration | — | 06021 |
| 28 Aug 2026, 12:10 | Results of Annual General Meeting | Meetings & Governance | — | 08003 |
| 28 Aug 2026, 09:38 | CEO Managing Director Presentation to Annual General Meeting | Presentations | — | 03026, 15002 |
| 6 Aug 2026, 10:09 | Bioshares Biotech Summit Presentation | Presentations | — | 03026 |
| 4 Aug 2026, 08:22 | Amplia signs Collaboration and Supply Agreement with Lilly | Company Update | MS | 11001 |
| 31 July 2026, 08:33 | Scientific Paper Studies of narmafotinib - Pancreatic Cancer | Company Update | — | 11001 |
| 29 July 2026, 08:29 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 |
| 27 July 2026, 16:14 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 |
| 15 July 2026, 18:27 | Notification regarding unquoted securities - ATX | Securities Administration | — | 06021 |
| 15 July 2026, 18:18 | Notification regarding unquoted securities - ATX | Securities Administration | — | 06021 |
| 13 July 2026, 09:37 | Amplia Therapeutics Shareholder Webinar | Presentations | — | 14014 |
| 6 July 2026, 16:43 | Initial Director's Interest Notice - Brett Carter | Director Interests | — | 02008 |
| 6 July 2026, 08:52 | Amplia Announces Appointment of Brett Carter to Board | Company Administration | — | 12001 |
| 1 July 2026, 08:20 | Annual General Meeting to be held Friday 28 August 2026 | Meetings & Governance | — | 08006 |
| 30 June 2026, 08:18 | Amplia Announces Changes to Board's Leadership Roles | Company Administration | — | 12017 |
| 25 June 2026, 08:17 | Notice of Initial Substantial Holding from SOL | Substantial Holders | — | 02001 |
| 24 June 2026, 14:51 | Becoming a substantial holder from PCG | Substantial Holders | — | 02001 |
| 29 May 2026, 15:38 | Appendix 4G - Key to Corporate Governance Disclosures | Company Administration | — | 03025 |
| 29 May 2026, 13:43 | Corporate Governance Statement 2026 | Company Administration | — | 03024 |
| 29 May 2026, 13:37 | Preliminary Final Report and Annual Report YE 31 March 2026 | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 |
| 19 May 2026, 08:18 | Amplia Launches First Stage of Pivotal Narmafotinib Trial | Company Update | MS | 11001 |
| 12 May 2026, 15:49 | Notice under Section 708A(5)(e) of the Corporations Act | Securities Administration | — | 06018 |
| 12 May 2026, 15:28 | Application for quotation of securities - ATX | Securities Administration | — | 06020 |
| 8 May 2026, 08:29 | Amplia and ANZGOG announce Ovarian Cancer Study | Company Update | MS | 11001 |
| 28 Apr 2026, 09:38 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 |
| 22 Apr 2026, 08:26 | ACCENT Trial Mature Data Presented at AACR Conference | Presentations | — | 03026 |
| 8 Apr 2026, 14:06 | Amplia MD Responds to Questions Regarding AMPLICITY Trial | Presentations | — | 14014 |
| 7 Apr 2026, 08:40 | Amplia Therapeutics Halts Recruitment in AMPLICITY Trial | Company Update | MS | 11001 |
| 23 Mar 2026, 09:35 | Amplia Reports Improved Responses & Survival in ACCENT trial | Company Update | MS | 09014, 11001 |
| 19 Mar 2026, 10:57 | Trading Halt | Trading Halt / Suspension | MS | 09007 |
| 19 Mar 2026, 09:52 | Pause in Trading | Trading Halt / Suspension | MS | 09005 |
| 9 Mar 2026, 08:14 | Benefit of Narmafotinib in kRas-Mutated Cancer Models | Company Update | — | 11001 |
| 25 Feb 2026, 08:10 | Appointment of Chief Financial Officer | Company Administration | — | 12008 |
| 18 Feb 2026, 08:11 | Amplia Emergence 2026 Conference Presentation | Presentations | — | 03026 |
| 11 Feb 2026, 09:09 | US Sites For AMPLICITY Pancreatic Cancer Trial Open | Company Update | — | 11001 |
| 30 Jan 2026, 08:28 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 |
| 22 Jan 2026, 16:44 | Change in substantial holding | Substantial Holders | — | 02002 |
| 22 Jan 2026, 08:21 | Narmafotinib Large-Scale Manufacture Complete | Company Update | — | 11001 |
| 9 Jan 2026, 16:20 | ACCENT Data Presented at 2026 ASCO GI Cancer Symposium | Company Update | — | 11001 |
| 19 Dec 2025, 08:26 | Amplia Enters 2nd Agreement with Drug Screening Co Next Bio | Company Update | — | 11001 |
| 11 Dec 2025, 19:56 | Additional Confirmed Response Reported-Investor Presentation | Presentations | — | 03026 |
| 3 Dec 2025, 08:30 | Key narmafotinib Patent Granted in the US | Company Update | — | 11001 |
| 27 Nov 2025, 16:44 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 |
| 20 Nov 2025, 09:59 | Positive Response from US FDA to Amplia's Type D Meeting | Company Update | MS | 11001 |
| 10 Nov 2025, 16:42 | Notification regarding unquoted securities - ATX | Securities Administration | — | 06021 |
| 31 Oct 2025, 08:19 | Amplia Commences Trading on U.S. OTCQB Venture Market | Securities Administration | — | 14011 |
| 29 Oct 2025, 09:03 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 |
| 28 Oct 2025, 09:13 | Amplia Receives R&D Tax Rebate Totalling $3.77 Million | Periodic Reports | MS | 03014 |